1398705-03-7

Upstream product

• 177947-96-5 tert-butyl 3-formylazetidine-1-carboxylate 
• 79175-35-2 3,4-dichlorophenylmagnesium bromide 
• 142253-55-2 1-(t-butyloxycarbonyl)-azetidine-3-carboxylic acid 
• 142253-56-3 3-hydroxymethyl-azetidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1398705-34-4 C₂₂H₂₅Cl₂NO₃ 
• 1398705-36-6 C₂₂H₂₅Cl₂NO₃ 
• 1398705-38-8 C₂₂H₂₅Cl₂NO₃ 
• 1398705-40-2 C₂₂H₂₅Cl₂NO₃ 
• 1398705-44-6 C₂₁H₂₂Cl₂FNO₃ 
• 1398705-46-8 C₂₁H₂₂Cl₂FNO₃ 
• 1398705-48-0 C₂₁H₂₂Cl₂FNO₃ 
• 1398705-50-4 C₂₁H₂₂Cl₃NO₃ 
• 1398705-52-6 C₂₁H₂₂Cl₃NO₃ 
• 1398705-54-8 C₂₁H₂₂Cl₃NO₃ 
• 1398705-56-0 C₂₂H₂₂Cl₂F₃NO₄ 
• 1398705-58-2 C₂₂H₂₂Cl₂F₃NO₄ 
• 1398705-60-6 C₂₂H₂₂Cl₂F₃NO₄ 
• 1398705-62-8 C₂₁H₂₁Cl₂F₂NO₃ 

Relevant academic research and scientific papers

Aromatic cycloamines derivative and application in multi-target antidepressant medicine

The invention discloses an aromatic cycloamines derivative and an application in multi-target antidepressant medicine. The aromatic cycloamines derivative has inhibitory activity on 5-HT reuptake, NEreuptake and DA reuptake, is a novel compound of a 5-HT/

AZETIDINE DERIVATIVE AND ANTIDEPRESSANT COMPOSITION INCLUDING THE SAME

The present invention relates to an azetidine derivative or a pharmaceutically acceptable salt thereof, and an antidepressant agent or a composition for the prevention or treatment of psychiatric disorders including the same. The azetidine derivative is useful as a triple reuptake inhibitor capable of inhibiting reuptake of the neurotransmitters, dopamine, serotonin, and norepinephrine at the same time.

AZETIDINE DERIVATIVE AND ANTIDEPRESSANT COMPOSITION CONTAINING SAME

The present invention relates to an azetidine derivative or a pharmaceutically acceptable salt thereof, and an antidepressant agent or a composition for the prevention or treatment of psychiatric disorders including the same. The azetidine derivative is useful as a triple reuptake inhibitor capable of inhibiting reuptake of the neurotransmitters, dopamine, serotonin, and norepinephrine at the same time.

Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors

Novel azetidines based on the 3-aryl-3-oxypropylamine scaffold were designed, synthesized, and evaluated as TRIs. Reduction of 1 followed by Swern oxidation and then Grignard reaction gave 3. The alkylation of 3 provided the corresponding azetidine derivatives 6, of which the two most promising, 6bd and 6be, were selected from 86 prepared analogues based on their biological profiles. Compound 6be showed activity in vivo in FST at 10 mg/kg IV or 20-40 mg/kg PO.